Iron-deficiency

Atrial Fibrillation

Ferritin, iron and iron binding capacity will be measured for evaluation of ID using Cobas c-e and Elecsys.
The relation of inflammation to iron deficiency will be evaluated by high sensitive C-reactive protein measurement.

Ferritin, iron and iron binding capacity, high sensitive C-reactive protein (CRP) measurement

Koc University

Prevalence and Clinical Associates of Iron Deficiency in Patients With Atrial Fibrillation

Prevalence and Clinical Associates of Iron Deficiency in Patients With Atrial Fibrillation (AID-AF)

To estimate the prevalence of iron deficiency in patients with atrial fibrillation

To estimate the prevalence of iron deficiency in patients with paroxysmal, persistent and permanent atrial fibrillation at enrollment.

The functional capacity of the patients will be assessed with 6-minute walk test

Thromboembolic risks will be assessed using CHADSVASC score

Bleeding risks will be assessed using HASBLED score

hs-CRP level (milligram/Liter) will be measured in patients with paroxysmal, persistent and permanent atrial fibrillation at enrollment

Koç University

Vifor (International) Inc.

Abdi Ibrahim Ilac San. ve Tic A.S.

100mg doses of the trial drug Kineret® will be administered subcutaneously (SC) twice daily (12 hourly) starting within 8 hours of symptoms onset for a maximum of 3 days from symptoms onset (or sooner if discharged from neurosurgical centre).

100mg doses of the placebo will be administered subcutaneously (SC) twice daily (12 hourly) starting within 8 hours of symptoms onset for a maximum of 3 days from symptoms onset (or sooner if discharged from neurosurgical centre).

Intracerebral Haemorrhage

Kineret® 100 mg in 0.67 ml Prefilled Syringe

IL-1Ra Kineret®

Placebo identical to Kineret® 100 mg in 0.67 ml Prefilled Syringe

IL-1Ra Placebo

Salford Royal NHS Foundation Trust

BLOC-ICH: Interleukin-1 Receptor Antagonist in Intracerebral Haemorrhage

Phase II Trial of Interleukin-1 Receptor Antagonist in Intracerebral Haemorrhage: BLOcking the Cytokine IL-1 in ICH

Perihaematomal OED on CT scan at 72 hours (+/-12 hours), which equates to the average distance that oedema extends beyond the haematoma border.

Early haematoma growth (defined as ≥33% or ≥6 ml increase in haematoma volume between baseline and 72 hours)

The average decrease of ≥2 in the Glasgow Coma Scale (GCS) score or an increase in the National Institutes of Health Stroke Scale (NIHSS) score ≥ 4, lasting longer than 8 h, requiring surgical intervention, or resulting in death.

Area under the curve for inflammatory markers of C-reactive protein (CRP) versus Interleukin-6 (IL-6)

Measure of the blood-brain barrier permeability in the perihaematomal brain using a tracer kinetic model, which generates maps of the blood-brain transfer constant K^trans

Measure of ordinal shift in degree of disability or dependence in daily activities

Severity of fatigue and it's effect on the participant's activities and lifestyle

cerebral hemorrhage/إعياء

Prevalence and Clinical Associates of Iron Deficiency in Patients With Atrial Fibrillation

BLOC-ICH: Interleukin-1 Receptor Antagonist in Intracerebral Haemorrhage

قاعدة بيانات الأعشاب الطبية الأكثر اكتمالا التي يدعمها العلم